SoftOx Solutions AS announced that the final patient in the fourth and last single-dose cohort of the SBE-01 clinical study has been treated today. This completes the first part (SAD* phase Ia) of SBE-01 and allows the study to advance to the last phase (MAD** phase Ib). SBE-01 (EudraCT no.

2021-000314-42) is the first-in-man (phase I) study with the SoftOx' lead wound care product, SBE (SoftOx Biofilm Eradicator), designed to treat infected chronic wounds. The study will establish a tolerable dose and treatment schedule for SBE to be able to develop it into an effective infection-treatment solution in problematic, non-healing wounds. With the upcoming final decision from the Safety Monitoring Committee, the MAD phase (Ib) will be activated.

In this part of the SBE-01 study we will test the tolerable SBE-products once or multiple times daily over 5 days. This will document even further on safety, tolerability, and efficacy when SBE is administered on a more intense and clinically relevant treatment schedule.